Content labelled as: MS news

Positive results for clinical trial in progressive MS

Blog post

Source MS Society:

Researchers in the US have proclaimed their initial test of ibudilast for MS a success.

Swiss Genomics Firm, Biogen and Microsoft Team Up to Treat Multiple Sclerosis

Blog post

Source Labiotech.eu

BC Platforms and Microsoft will be working with Biogen and the Accelerated Cure Project to study the genetics of multiple sclerosis and accelerate research.

A message from Trishna

Blog post

A message from Trishna

I've been asked to help source participants for a focus group that I'm attending to look at a new patient platform that has been developed to make the clinical trials process more patient-friendly.

Don't get caught out in a power cut - register with the free SSE Priority Service

Blog post

It doesn't matter who your electricity supplier is, if you are disabled you can register to receive the SSE Priority Service.

3D printing brain scans helps doctors with a tricky diagnosis

Blog post

Source Tech Crunch:

When there’s a problem in the brain, it pays to be precise — every millimeter counts with something like a tumor or blocked artery.

Need Financial Assistance@

Blog post

Source MS Society:

Need Financial Assistance? Who can help?

End to ESA reassessments comes into effect

Blog post

Source MS Society:

From the 29th September, some people with MS won't have to be re-tested for Employment and Support Allowance (ESA) after their next reassessment.

Last October the Government announced it would stop ESA reassessments for people with severe conditions who can't...

Long-term Lemtrada Treatment Benefits Demonstrated in Extension Study

Blog post

Source Multiple Sclerosis News Today:

A five-year study demonstrated that Sanofi-Genzyme’s Lemtrada (alemtuzumab) provides long-term benefits for relapsing-remitting multiple sclerosis patients, reducing relapse rates and preventing the progression of the disease.

Importantly,...

New study to look at impact of early treatment with aggressive DMTs

Blog post

Source MS Society:

A new study will investigate whether early treatment with aggressive disease modifying therapies (DMTs) could benefit people with MS.

Disarm Therapeutics to Begin Developing Therapy that Prevents Axonal Degeneration

Blog post

Source Multiple Sclerosis News Today:

Disarm Therapeutics has completed the first round of financing to develop a compound that prevents axonal degeneration in patients with multiple sclerosis (MS) and other neurodegenerative conditions.

Pages

Subscribe to Content labelled as: MS news